FAO-ANIMALHEALTH-L Archives

Establishment of a PPR Global Research and Expertise Network (PPR-GREN)

FAO-AnimalHealth-L@LISTSERV.FAO.ORG

Options: Use Forum View

Use Monospaced Font
Show HTML Part by Default
Show All Mail Headers

Message: [<< First] [< Prev] [Next >] [Last >>]
Topic: [<< First] [< Prev] [Next >] [Last >>]
Author: [<< First] [< Prev] [Next >] [Last >>]

Print Reply
Subject:
From:
Emmanuel Albina <[log in to unmask]>
Reply To:
Emmanuel Albina <[log in to unmask]>
Date:
Wed, 26 Feb 2014 10:45:45 -0400
Content-Type:
multipart/alternative
Parts/Attachments:
text/plain (3015 bytes) , text/html (4 kB)
Dear all,

To answer directly to the question of capripoxvirus recombinant vaccine 
approach developed by CIRAD, we have generated H-PPR and F-PPR 
recombinant capripoxviruses that protect against both diseases. We also 
generated recombinant Rift Valley fever-capripoxvirus that is 
imunologically active (no challenge studies so far). We are thinking 
about a trivalent vaccine, for instance PPR-Rift-capripoxvirus.

The advantages of the capripoxvirus in our hands are:

- easy platform to insert and express in target animals several 
different transgenes (e.g.:  a perfectly characterized immunogen of 
Brucella could be inserted and tested)
- long lasting immunity after one shoot (at least one year of protection)
- DIVA property for the diseases targeted by the inserts (in the case of 
PPR, we induce anti-H or anti-F immune responses and we test the serum 
anti-N antibodies by a commercial ELISA)
- thermal stability (2 weeks in liquid form at +36°C)

However, the current drawbacks are:

- validations are still required before use in the field: purity check 
(possibly by deep sequencing without a priori), upscaling of the 
production, etc... (according to the requirements of the private 
industry and international regulations)
- pre-immunity interference with the vaccine: first vaccination with 
this type of vaccine in a ruminant population infected by wild-type 
capripoxvirus may not protect more than 50% of the animals against pox 
_AND_ PPR. This means that the first year, a combination of recombinant 
capripox and Nigeria75/1 vaccine [a paper in Vaccine (Chaudary et al, 
2009) showed that both vaccines could be combined in a single injection] 
should be applied to reduce the prevalence of capripoxvirus and then the 
next year, only the recombinant capripoxvirus could be used
- Lack of funds to speed up finalization of laboratory work before 
transfer of the vaccine to the private sector

Regards

For CIRAD, Emmanuel Albina


Le 25/02/2014 12:19, Paul Rossiter a écrit :
> Dear moderator and dear all,
> I agree with that we should include other diseases such as sheep and 
> goats pox in the progressive control of PPR in small ruminants. If I 
> well remember Cirad had in collaboration with LANAVET 
> (Cameroon) developped recombinant vaccine against PPR using Capripox 
> as support. I don't know if this vaccine is still available ; if yes 
> so we can easily go for progressive control of PPR and SGP. I think Dr 
> Adama or Ngagnou could answer to this.
> Kind regards!
> Bidjeh Kebkiba,
> Head of virology Unit, IRED (Chad),
> Route de farcha,
> PO box 433, Ndjamena- Chad.
>
> ------------------------------------------------------------------------
>
> To unsubscribe from the FAO-AnimalHealth-L list, click the following link:
> https://listserv.fao.org/cgi-bin/wa?SUBED1=FAO-AnimalHealth-L&A=1
>

-- 
Signature electronique

########################################################################

To unsubscribe from the FAO-AnimalHealth-L list, click the following link:
https://listserv.fao.org/cgi-bin/wa?SUBED1=FAO-AnimalHealth-L&A=1


ATOM RSS1 RSS2